Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of July 12, 2025 • 8:00 AM ET

Date/Time Source News Release
07/07/2025 05:30 PM EDT Newsfile NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update
07/03/2025 04:41 PM EDT Newsfile NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
07/01/2025 07:30 AM EDT Newsfile NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
06/18/2025 07:30 AM EDT Newsfile NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
06/02/2025 07:00 AM EDT GlobeNewswire NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
05/21/2025 07:30 AM EDT Newsfile NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
05/16/2025 04:30 PM EDT Newsfile NervGen Pharma Grants Stock Options
05/15/2025 07:30 AM EDT Newsfile NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
05/07/2025 07:30 AM EDT Newsfile NervGen Pharma Announces Results of Annual General Meeting of Shareholders
04/21/2025 07:30 AM EDT Newsfile NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Page

Additional News

As of July 12, 2025 • 8:00 AM ET

Date/Time Source News Release
06/20/2025 09:28 AM EDT SeekingAlpha Undercovered Dozen: Rigetti Computing, Western Union, Ouster And More
06/13/2025 09:00 AM EDT SeekingAlpha NervGen Pharma: Risky, Yet Promising With Big Upside
05/30/2025 03:00 PM EDT SeekingAlpha Catalyst Watch: Crypto buzz with the Circle IPO, Snowflake event and the May Jobs Report
05/23/2025 03:00 PM EDT SeekingAlpha Catalyst Watch: Eyes on Nvidia, OPEC, and box office blockbusters
05/15/2025 10:10 AM EDT SeekingAlpha NervGen Pharma GAAP EPS of -$0.06
01/10/2025 04:37 AM EST SeekingAlpha NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
12/28/2024 01:00 PM EST SeekingAlpha Undercovered Dozen: OppFi, PowerFleet, Eletrobras, American Battery +
12/25/2024 01:25 AM EST SeekingAlpha NervGen: Data For Spinal Cord Injury Treatment Candidate Likely For Mid-2025
11/15/2024 03:33 AM EST SeekingAlpha NervGen Pharma GAAP EPS of -$0.07
08/23/2024 12:32 PM EDT SeekingAlpha NervGen Pharma reports Q2 results
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.